StockNews.AI
HIMS
StockNews.AI
21 days

Levi & Korsinsky Reminds Hims & Hers Health, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - HIMS

1. HIMS faces a class action lawsuit for alleged securities fraud. 2. Lawsuit claims misleading statements about knockoff versions of Wegovy®. 3. Potential termination of partnership with Novo Nordisk is at stake. 4. Investors affected between April and June 2025 can participate. 5. Legal representation is offered at no cost to affected investors.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit could lead to reputational damage and financial liability for HIMS, reminiscent of past cases where companies faced significant stock declines after similar allegations. Historical precedents show stocks often drop sharply when legal challenges arise, especially surrounding fraud allegations.

How important is it?

The severity of the allegations and their potential impact on partnerships, like with Novo Nordisk, indicates a significant risk to HIMS’s market position and financial health, warranting a high importance score.

Why Short Term?

The immediate implications of the lawsuit could cause volatility in HIMS's stock price, particularly as the lawsuit unfolds and investor sentiment reacts. Legal disputes typically have short to medium-term impacts on stock prices, often causing rapid declines in the short term.

Related Companies

NVDAPFEAMGN
, /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/hims-hers-health-inc-lawsuit-submission-form?prid=158412&wire=4  HIMS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;" (2) as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in Hims & Hers Health, Inc. during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News